Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200

Amicus Therapeutics is building on strong commercial momentum from its approved drugs, projecting $1 billion in revenue by 2028, while strategically expanding its pipeline with the licensed DMX-200 for Focal Segmental Glomerulosclerosis (FSGS). This Phase 3 candidate targets a significant unmet medical need and has shown positive initial interim data, with the FDA agreeing to proteinuria as an approvable endpoint. Although the DMX-200 licensing deal impacts Amicus's immediate cash position, the company retains access to an ATM facility for funding, and Dimerix is responsible for funding the ongoing Phase 3 study, with key catalysts including a second interim analysis and enrollment completion by year-end 2025.

Analysis

Amicus Therapeutics (NASDAQ:FOLD) presents a dual-pronged investment thesis, combining a robust commercial base with a high-potential clinical pipeline. The company's existing products, GALAFOLD and POMBILITI/OPFOLDA, are demonstrating significant commercial traction, with Q2 2025 sales growth of 12% and 58% at constant exchange rates, respectively. This performance underpins the company's guidance to achieve $1 billion in total revenue by 2028. Strategically, Amicus has expanded into the lucrative nephrology space by licensing DMX-200 from Dimerix for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with no approved treatments and a projected global market of $51.72 billion by 2034. The clinical program for DMX-200 is notably de-risked following a positive first interim analysis in its Phase 3 ACTION3 trial and an agreement with the FDA to use proteinuria as an approvable primary endpoint. Key upcoming catalysts include a second blinded interim analysis and the completion of patient enrollment by the end of 2025, which will be critical inflection points ahead of the final data expected in 2029. Financially, the company's cash position of $231 million provides a runway of at least 12 months, with immediate funding concerns mitigated by a remaining $164.2 million capacity in its ATM facility with Goldman Sachs and the favorable deal structure where Dimerix bears the cost of the ongoing Phase 3 trial.

Key Decisions for Investors

• Investors should evaluate Amicus based on its dual growth drivers: the stable, double-digit revenue growth from its commercial portfolio in Pompe and Fabry diseases, and the higher-risk, high-reward potential of the DMX-200 asset in the large, untapped FSGS market.
• The upcoming second blinded interim analysis for the Phase 3 ACTION3 study and the completion of enrollment by year-end 2025 are crucial near-term catalysts that could significantly impact the stock's valuation and should be monitored closely.
• While the company's stated cash runway is limited to about 12 months, the risk is partially offset by a $164.2 million ATM facility, an important consideration for assessing near-term financing risk and potential dilution.
• Consider the long-term value creation potential from the DMX-200 licensing deal, which grants Amicus U.S. rights for all future indications, offering upside beyond the initial FSGS target that is not yet fully reflected in the company's valuation.